Company intelligence / Profile preview

New Amsterdam Marketing

Naarden, Netherlands

Ownership: Private
Development stage: Other

Overview

Obicetrapib monotherapy achieved LS mean LDL-C reduction of 36% (p < 0.0001) vs placebo at day 84 in BROOKLYN trial; positive topline data from BROADWAY and TANDEM trials with LDL-C reductions and placebo-like safety; PREVAIL outcomes trial ongoing with >9,500 patients enrolled.[2][5]

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Menarini GroupVictorian Health Institute

Beyond the preview

Go deeper on New Amsterdam Marketing.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Amsterdam Marketing.

Explore the full profile